文献速递消化道肿瘤放疗放疗物理与技术姑息放疗与转移瘤

立体定向消融放疗(SABR)作为胰腺癌原发、辅助、巩固及再治疗选择:剂量提升空间与毒性教训

Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
PubMed 文献 · Radiat Oncol · 2018-10-19

研究纳入42例不可手术非转移性胰腺癌患者,接受CyberKnife® SABR(18-36 Gy分3次)作为原发、辅助、巩固或再治疗。仅8.1%出现3级急性毒性,但12.5%出现4级十二指肠毒性;线性二次模型显示50%患者最低PTV剂量低于常规放疗方案,提示剂量提升空间。

要点

  • 42例不可手术非转移性胰腺癌接受18-36 Gy分3次SABR,37例(88%)为T4期。
  • 3/37(8.1%)出现3级急性毒性,4/32(12.5%)出现4级十二指肠毒性。
  • 中位无局部进展生存9.8个月,中位总生存8.4个月;2例(4.8%)转为可切除。

核心结论

  • SABR对胰腺癌多种适应证有价值;剂量提升以提高BED可能改善不可手术非转移性疾病的FFLP和OS,但需同时加强对十二指肠的保护。

研究设计与样本

  • 研究纳入42例不可手术非转移性胰腺癌患者,接受CyberKnife® SABR(18-36 Gy)分3次,作为原发、辅助、巩固或再治疗选择。
  • 收集患者个体化计划和实施变量,分析其对结局的影响,并应用线性二次(LQ)放射生物学模型将SABR参数与常规分次放疗方案比较。

主要发现

  • 37例(88%)为T4期;SABR用于原发治疗后>6个月再治疗残留病灶11例(26.2%)、复发灶9例(21.4%)、辅助其他原发治疗14例(33.3%)、唯一原发治疗8例(19.0%)。
  • 平均(95%CI)PTV为76.3(63.8-88.7)cc,处方等剂量线67.3(65.2-69.5)%,百分比覆盖96.6(95.5-97.7)%,PTV最低剂量22.3(21.0-23.6)Gy,BED为50.3(47.7-53.0)Gy。
  • 仅3/37(8.1%)出现3级急性毒性;2例(4.8%)转为可切除;中位FFLP和OS分别为9.8和8.4个月。
  • 27/32(84.4%)无晚期毒性;4例(12.5%)出现4级十二指肠毒性,其中2例PTV特别大、2例基准标记数量欠佳、3例突破OAR约束。
  • 实施时间较长、治疗疗程延长和百分比覆盖降低与晚期毒性相关;较大PTV和较长疗程与OS相关。

关键数值与推荐

  • LQ模型比较分析显示50%患者接受的PTV最低剂量效力低于常规放疗方案,提示有剂量提升空间。
  • 剂量提升以提高BED可能改善不可手术非转移性疾病的FFLP和OS,但必须同时加强对十二指肠的保护。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic ablative radiotherapy (SABR) offers an alternative treatment for pancreatic cancer, with the potential for improved tumour control and reduced toxicity compared with conventional therapies. However, optimal dose planning and delivery strategies are unelucidated and gastro-intestinal (GI) toxicity remains a key concern. METHODS: Patients with inoperable non-metastatic pancreatic cancer who received CyberKnife® SABR (18-36 Gy) in three fractions as primary, adjuvant, consolidation or re-treatment options were studied. Patient individualised planning and delivery variables were collected and their impact on patient outcome examined. Linear-quadratic (LQ) radiobiology modelling methods were applied to assess SABR parameters against a conventional fractionated radiotherapy schedule. RESULTS: In total 42 patients were included, 37 (88%) of whom had stage T4 disease. SABR was used > 6 months post-primary therapy to re-treat residual disease in 11 (26.2%) patients and relapsed disease in nine (21.4%) patients. SABR was an adjuvant to other primary therapy for 14 (33.3%) patients and was the sole primary therapy for eight (19.0%) patients. The mean (95% CI) planning target volume (PTV), prescription isodose, percentage cover, minimum dose to PTV and biological effective dose (BED) were 76.3(63.8-88.7) cc, 67.3(65.2-69.5)%, 96.6(95.5-97.7)%, 22.3(21.0-23.6) Gy and 50.3(47.7-53.0) Gy, respectively. Only 3/37 (8.1%) patients experienced Grade 3 acute toxicities. Two (4.8%) patients converted to resectable status and median freedom-from-local-progression (FFLP) and overall survival (OS) were 9.8 and 8.4 months, respectively. No late toxicity was experienced in 27/32 (84.4%) patients; however, four (12.5%) patients - of whom two had particularly large PTV, two had sub-optimal number of fiducials and three breached organ-at-risk (OAR) constraints-showed Grade 4 duodenal toxicities. Longer delivery time, extended treatment course and reduced percentage coverage additionally associated with late toxicity, likely reflecting parameters typically applied to riskier patients. Larger PTV size and longer treatment course associated with OS. Comparator regimen LQ modelling analysis indicated 50% of patients received minimum PTV doses less potent than a conventional radiotherapy regimen, indicating scope for dose escalation. CONCLUSION: The results demonstrate the value of SABR for a range of indications in pancreatic cancer. Dose escalation to increase BED may improve FFLP and OS in inoperable, non-metastatic disease: however concomitant enhanced stringency for duodenal protection is critical, particularly for patients where SABR is more challenging.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Goldsmith C, Plowman PN, Green MM, et al. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity. Radiat Oncol. 2018. PMID: 30340643. doi:10.1186/s13014-018-1138-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。